Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin

Molecular Therapy

Volumn 20, Issue 5, 2012, Pages 948-953

  Karikó, Katalin ^a   Muramatsu, Hiromi ^a   Keller, Jason M ^b   Weissman, Drew ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ERYTHROPOIETIN; INTERLEUKIN 6; MESSENGER RNA; PSEUDOURIDINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG MECHANISM; ERYTHROPOIESIS; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; HEMATOCRIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETICULOCYTE COUNT; RHESUS MONKEY; RNA PURIFICATION; RNA TRANSLATION;

MACACA; MUS;

EID: 84860539841     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.7     Document Type: Article

References (34)

1. Jirikowski, GF, Sanna, PP, Maciejewski-Lenoir, D and Bloom, FE (1992). Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science 255: 996-998.
2. Weide, B, Carralot, JP, Reese, A, Scheel, B, Eigentler, TK, Hoerr, I et al. (2008). Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 31: 180-188.
3. Weide, B, Pascolo, S, Scheel, B, Derhovanessian, E, Pflugfelder, A, Eigentler, TK et al. (2009). Direct injection of protamine-protected mRNA: results of a phase vaccination trial in metastatic melanoma patients. J Immunother 32: 498-507.
4. Rittig, SM, Haentschel, M, Weimer, KJ, Heine, A, Muller, MR, Brugger, W et al. (2011). Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19: 990-999.
5. Kreiter, S, Diken, M, Selmi, A, Türeci, Ö and Sahin, U (2011). Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol 23: 399-406.
6. Karikó, K, Ni, H, Capodici, J, Lamphier, M and Weissman, D (2004). mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 279: 12542-12550. (Pubitemid 38445825)
7. Diebold, SS, Kaisho, T, Hemmi, H, Akira, S and Reis e Sousa, C (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531. (Pubitemid 38314425)
8. Karikó, K, Buckstein, M, Ni, H and Weissman, D (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165-175. (Pubitemid 41169286)
9. Hornung, V, Ellegast, J, Kim, S, Brzózka, K, Jung, A, Kato, H et al. (2006). 5'-Triphosphate RNA is the ligand for RIG-I. Science 314: 994-997.
10. Nallagatla, SR, Hwang, J, Toroney, R, Zheng, X, Cameron, CE and Bevilacqua, PC (2007). 5'-triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science 318: 1455-1458. (Pubitemid 350208957)
11. Anderson, BR, Muramatsu, H, Nallagatla, SR, Bevilacqua, PC, Sansing, LH, Weissman, D et al. (2010). Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res 38: 5884-5892.
12. Anderson, BR, Muramatsu, H, Jha, BK, Silverman, RH, Weissman, D and Karikó, K (2011). Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res 39: 9329-9338.
13. Nallagatla, SR and Bevilacqua, PC (2008). Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner. RNA 14: 1201-1213. (Pubitemid 351717499)
14. Karikó, K, Muramatsu, H, Welsh, FA, Ludwig, J, Kato, H, Akira, S et al. (2008). Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16: 1833-1840.
15. Kormann, MS, Hasenpusch, G, Aneja, MK, Nica, G, Flemmer, AW, Herber-Jonat, S et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 29: 154-157.
16. Karikó, K, Muramatsu, H, Ludwig, J and Weissman, D (2011). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 39: e142.
17. Kramer, M, Schulte, BM, Eleveld-Trancikova, D, van Hout-Kuijer, M, Toonen, LW, Tel, J et al. (2010). Cross-talk between human dendritic cell subsets influences expression of RNA sensors and inhibits picornavirus infection. J Innate Immun 2: 360-370.
18. Kim, CH, Oh, Y and Lee, TH (1997). Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells. Gene 199: 293-301. (Pubitemid 27448231)
19. Lee, DE, Son, W, Ha, BJ, Oh, MS and Yoo, OJ (2006). The prolonged half-lives of new erythropoietin derivatives via peptide addition. Biochem Biophys Res Commun 339: 380-385. (Pubitemid 41697561)
20. Casadevall, N, Nataf, J, Viron, B, Kolta, A, Kiladjian, JJ, Martin-Dupont, P et al. (2002). Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469-475. (Pubitemid 34441737)
21. Bennett, CL, Cournoyer, D, Carson, KR, Rossert, J, Luminari, S, Evens, AM et al. (2005). Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a followup report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 106: 3343-3347. (Pubitemid 41609162)
22. Gao, G, Lebherz, C, Weiner, DJ, Grant, R, Calcedo, R, McCullough, B et al. (2004). Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103: 3300-3302. (Pubitemid 38525655)
23. Chenuaud, P, Larcher, T, Rabinowitz, JE, Provost, N, Cherel, Y, Casadevall, N et al. (2004). Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 103: 3303-3304. (Pubitemid 38525656)
24. Hedman, M, Hartikainen, J and Ylä-Herttuala, S (2011). Progress and prospects: hurdles to cardiovascular gene therapy clinical trials. Gene Ther 18: 743-749.
25. Kromminga, A and Schellekens, H (2005). Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann N Y Acad Sci 1050: 257-265. (Pubitemid 41129443)
26. Kharagjitsingh, AV, Korevaar, JC, Vandenbroucke, JP, Boeschoten, EW, Krediet, RT, Daha, MR et al.; NECOSAD Study Group. (2005). Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Int 68: 1215-1222. (Pubitemid 43246439)
27. Gustafsson, C, Govindarajan, S and Minshull, J (2004). Codon bias and heterologous protein expression. Trends Biotechnol 22: 346-353. (Pubitemid 38887543)
28. Zhong, F, Cao, W, Chan, E, Tay, PN, Cahya, FF, Zhang, H et al. (2005). Deviation from major codons in the Toll-like receptor genes is associated with low Toll-like receptor expression. Immunology 114: 83-93. (Pubitemid 40030296)
29. Ngumbela, KC, Ryan, KP, Sivamurthy, R, Brockman, MA, Gandhi, RT, Bhardwaj, N et al. (2008). Quantitative effect of suboptimal codon usage on translational efficiency of mRNA encoding HIV-1 gag in intact T cells. PLoS ONE 3: e2356.
30. Raper, SE, Chirmule, N, Lee, FS, Wivel, NA, Bagg, A, Gao, GP et al. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80: 148-158. (Pubitemid 37272241)
31. Morgan, RA, Yang, JC, Kitano, M, Dudley, ME, Laurencot, CM and Rosenberg, SA (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851.
32. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419. (Pubitemid 37296260)
33. Weissman, D, Ni, H, Scales, D, Dude, A, Capodici, J, McGibney, K et al. (2000). HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol 165: 4710-4717.
34. Rivera, VM, Gao, GP, Grant, RL, Schnell, MA, Zoltick, PW, Rozamus, LW et al. (2005). Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105: 1424-1430. (Pubitemid 40223657)